Data completeness
0/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYSTAFORM is a topical ointment combining clioquinol and nystatin for dermatological fungal and microbial infections. The combination leverages nystatin's antifungal activity against Candida species with clioquinol's broad-spectrum antimicrobial properties. This fixed-dose combination targets inflammatory and infectious skin conditions.
Pre-Launch
As a pre-launch topical product, commercial teams are focused on market preparation and may be lean; career growth depends on successful market entry and formulary positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NYSTAFORM offers entry or transition opportunities in pre-launch brand building and market access strategy for a dermatology-focused product. Career progression will depend on successful launch execution and ability to navigate a competitive generic-dominated landscape.
Brand ManagerProduct Manager
Worked on NYSTAFORM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.